OKUR OnKure Therapeutics, Inc.
Legal ·
Thomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board.
The company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026.
The amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting.
OnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines that target biologically validated drivers of cancers and other diseases underserved by available therapies. It uses a structure-based drug design platform to build small molecule drugs that selectively target mutated forms of proteins. Its lead product candidate, OKI-219, is a highly selective inhibitor of PI3Kα harboring the H1047R mutation, with approximately 80-fold selectivity for the mutated form over the wild-type enzyme. The company plans to initially focus OKI-219 on advanced breast cancer in genetic subtypes that are hormone receptor positive and HER2 negative, and HER2 positive. OKI-219 is being investigated in the first-in-human Phase 1 open-label PIKture-01 trial in patients with solid tumors. Enrollment is complete in Part A, the monotherapy arm, and Part B, the fulvestrant combination arm, while Parts C and E are enrolling.
| Product or program | What it is | Stage |
|---|---|---|
| OKI-219 | Highly selective inhibitor of mutant PI3Kα H1047R for advanced breast cancer | Phase 1 (PIKture-01) |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | |
| Research and development | $48.3 million | $43.8 million |
| Net income (loss) | -$59.5 million | -$52.7 million |
| Cash from operations | -$51.8 million | -$51.1 million |
| Cash and equivalents | $59.0 million | $110.8 million |
| Short-term investments | $0 |
Our latest story on this, dated Aug 4, 2026: "OnKure files $100,000,000 at-the-market stock sale supplement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 4, 2026: "OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy". The story links the filing or release it is based on. Read the story.
OnKure Therapeutics, Inc. trades under the ticker OKUR on NASDAQ.
OnKure Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for OnKure Therapeutics, Inc. is 1637715. Its filings are on SEC EDGAR.
40,496,309 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04.
Our directory records OnKure Therapeutics, Inc. under United States.
Our directory classifies OnKure Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for OnKure Therapeutics, Inc. is US68277Q1058.
aibio.space lists OnKure Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines that target biologically validated drivers of cancers and other diseases underserved by available therapies. It uses a structure-based drug design platform to build small molecule drugs that selectively target mutated forms of proteins.
OKI-219: Highly selective inhibitor of mutant PI3Kα H1047R for advanced breast cancer Stage: Phase 1 (PIKture-01).
OnKure Therapeutics, Inc. reported a net loss of $59.5 million for the fiscal year ended Dec 31, 2025, and used $51.8 million of cash in operations, per its annual report to the SEC.
$48.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio